Company news
Kairos Pharma, Ltd. (AMEX:KAPA) news
Every Kairos Pharma, Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Kairos Pharma Announces 1-for-7 Reverse Stock Split
August 21, 2026
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10...
July 15, 2026
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
June 4, 2026
Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award
May 14, 2026
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
May 13, 2026
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
May 8, 2026
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
April 15, 2026
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pi...
March 2, 2026
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
February 26, 2026
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
January 20, 2026
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
December 17, 2025
Kairos Pharma Provides Shareholder Update
November 4, 2025
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
October 20, 2025
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
October 7, 2025
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression...
September 18, 2025
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
September 11, 2025
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Ca...
September 3, 2025
Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
July 16, 2025
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
July 15, 2025
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American So...
June 4, 2025
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American So...
June 3, 2025
Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference
May 6, 2025
Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
April 28, 2025
Kairos Pharma Ltd. Provides Letter to Stockholders
April 24, 2025